ÂÜÀòÂÒÂ×

Geoff Yarranton is an experienced molecular biologist/biochemist whose leadership experience in the biotech industry spans more than 35 years. His scientific acumen is matched by a robust understanding of operational and business logistics, with a focus on the domestic and international drug approval process, as evidenced by his close involvement in the development of FDA-approved biopharmaceutical products including Mylotarg, Bexxar, and Cimzia.

Geoff has overseen two successful bio/pharma mergers and guided KaloBios Pharmaceuticals through its IPO. His practical knowledge of the entire pharmaceutics lifecycle, from drug discovery to R&D to patenting to manufacturing, makes him a resource of immense value to EnGen. Geoff holds 23 issued patents.

Geoffrey has a BSc (Hons) from University of Leicester (UK), a Ph.D. from National Institute for Medical Research (UK), and a postdoctoral fellowship, MIT.